Becton, Dickinson and Company

773 articles with Becton, Dickinson and Company

• BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

  6/30/2022

  BD, a leading global medical technology company, announced that the BD MAX™ Respiratory Viral Panel, a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus, has been CE marked to the IVD directive 98/79/EC.

• BD Announces Voluntary Recall on Intraosseous Products

  6/22/2022

  BD, a leading global medical technology company, announced a voluntary recall on the BD™ Intraosseous Needle Set Kits, BD™ Intraosseous Manual Driver Kits and BD™ Intraosseous Powered Drivers.

• Eastern Health and BD Implement Innovative Solution with Goal of Reducing Consumption of Antibiotics and Other Medications

  6/22/2022

  BD, a leading global medical technology company, is pleased to announce the integration of the BD HealthSight™ Analytics Solutions in Eastern Health facilities.

• CerTest Biotec and BD Announce Collaboration on Molecular Diagnostic Test for Monkeypox

  6/8/2022

  CerTest Biotec and BD, a leading global medical technology company, announced a collaboration to develop a molecular diagnostic test for the Monkeypox virus.

• BD Names Simon Campion as Medical Segment President

  6/7/2022

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has appointed Simon Campion as executive vice president (EVP) and president of the Medical segment for BD, effective July 1, 2022.

• BD TO ACQUIRE PARATA SYSTEMS TO ENTER NEW PHARMACY AUTOMATION SOLUTIONS MARKET

  6/6/2022

  Expands BD Transformative Solutions to Provide New Pharmacy Automation Technologies for Hospitals, Retail Pharmacy, Long-Term Care and Home Settings.

• BD Unveils World's First Spectral Cell Sorter with High-Speed Imaging Technology that Sorts Cells Based on Visual Characteristics

  6/3/2022

  BD FACSDiscover™ S8 Cell Sorter with BD CellView™ Image Technology First to Combine Spectral Flow Cytometry with Sort-Capable Imaging.

• BD to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

  6/2/2022

  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:00 a.m. Eastern Time.

• BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S.

  5/12/2022

  BD, a leading global medical technology company, announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform.

• Babson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New Care Settings

  5/11/2022

  Babson Diagnostics and BD announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing.

• BD Reports Second Quarter Fiscal 2022 Financial Results

  5/5/2022

  BD, a leading global medical technology company, announced results for its second quarter of fiscal year 2022, which ended March 31, 2022.

• BD Board Declares Dividend - Apr 26, 2022

  4/26/2022

  The Board of Directors of BD has declared a quarterly dividend of $0.87 per common share, payable on June 30, 2022 to holders of record on June 9, 2022.

• New BD Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry

  4/25/2022

  BD announced the launch of a new family of reagents that enables researchers to gain improved data resolution and greater insights from samples compared to traditional fluorochromes, made possible by their innovative development using novel dye technology and artificial intelligence guidance.

• BD Forms Sustainable Medical Technology Institute to Reduce the Environmental Impact of its Product Portfolio

  4/22/2022

  BD (Becton, Dickinson and Company) today announced the formation of the Sustainable Medical Technology Institute.

• BD Announces Completion of Embecta Corp. Spinoff

  4/1/2022

  BD, a leading global medical technology company, announced that it has completed its spinoff of Embecta Corp., which holds BD's former Diabetes Care business and is now one of the largest pure-play diabetes management companies in the world.

• Alberto Mas Announces Intent to Retire from BD at End of Fiscal Year

  3/31/2022

  BD, a leading global medical technology company, announced that Alberto Mas has informed the company of his intent to retire from BD, effective at the end of the company's fiscal year on Sept. 30, 2022.

• BD Announces Early Tender Results for Cash Tender Offers by Morgan Stanley & Co. LL

  3/30/2022

  BD announced the early results and pricing terms of Morgan Stanley & Co. LLC's previously announced cash tender offers for the notes set forth below, up to a maximum aggregate combined purchase price on such Notes payable in connection with such Offers) of $200,000,000.00.

• BD Provides Update Regarding the Planned Spinoff of Embecta Corp.

  3/21/2022

  BD, a leading global medical technology company, provided additional details related to the planned spinoff of Embecta Corp..

• BD Announces Cash Tender Offers by Morgan Stanley & Co. LLC

  3/16/2022

  BD, a leading global medical technology company announced that Morgan Stanley & Co. LLC has commenced cash tender offers for the notes set forth below, up to a maximum aggregate combined purchase price on such Notes payable in connection with such Offers) of $200,000,000.00.

• BD Names William 'Bill' Brown to Board of Directors

  3/1/2022

  BD, a leading global medical technology company, announced the appointment of William "Bill" Brown to its board of directors, effective Feb. 28, 2022.